



INFORMAZIONI PERSONALI

Nome
Indirizzo
Telefono
E-mail

OCCHIPINTI MARIO

VIA GIACOMO VENEZIAN, 1, 20133 MILANO, ITALIA.

0223903039

mario.occhipinti@istitutotumori.mi.it

ESPERIENZE LAVORATIVE

Dall' 11 Dicembre 2020 ad oggi

Medico Oncologo presso Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Unità di Oncologia Toracica, Via Giacomo Venezian 1, 20133, Milano, Italia

Contratto di collaborazione professionale.

Dal 20 Novembre 2020 al 10 Dicembre 2020

Medico Oncologo presso Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Unità di Oncologia Toracica, Via Giacomo Venezian 1, 20133, Milano, Italia

Contratto di collaborazione occasionale nell'ambito del "Progetto reti tumori epiteliali timici"

Dal 14 Aprile 2020 al 31 Ottobre 2020

Periodo di formazione presso Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Unità di Oncologia Toracica, Via Giacomo Venezian 1, 20133, Milano, Italia

Medico in formazione specialistica in Oncologia Medica

Dall'11 Maggio 2017 al 13 Aprile 2020

Università di Roma "La Sapienza", Unità di Oncologia Medica B, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italia

Medico in formazione specialistica in Oncologia Medica

Dal 9 Novembre 2015 all' 11 Maggio 2017

Università di Roma "La Sapienza", Unità di Oncologia Medica, Ospedale Sant'Andrea, 1035-1039, Via di Grottarossa, 00189, Rome, Italia

Medico in formazione specialistica in Oncologia Medica

EDUCAZIONE E FORMAZIONE

Dal 9 Novembre 2020 al 22 Aprile 2024

Università di Roma "La Sapienza", Dipartimento di Medicina Sperimentale, Dottorato di ricerca in Network Oncology and Precision Medicine

Dottorando di ricerca

Dal 2 Novembre 2015 al 31 Ottobre 2020

Università di Roma "La Sapienza", Scuola di Specializzazione in Oncologia Medica

Medico specialista in Oncologia Medica. Voto: 70/70 e lode.

Tesi: « Valutazione dei drug-drug interactions (DDIs) nei pazienti affetti da neoplasia polmonare »

Dal 3 Novembre 2014 al 5 Febbraio 2015

Università di Roma "La Sapienza"

Abilitazione alla professione di Medico Chirurgo
Registro all'Ordine dei Medico della provincia di Bari numero 15256
Abilitazione alla professione di Medico Chirurgo

Dall' Ottobre 2008 al Settembre 2014

Facoltà di Medicine e Psicologia, Università di Roma "La Sapienza"
Laurea magistrale a ciclo unico in Medicina e Chirurgia. Voto: 110/110 e lode.

Tesi: « Effect of Degradation Rate of 5-FU and genetic polymorphisms of DPYD, TSER and MTHFR on toxicity and survival of 5-FU-based chemotherapy in colon-rectal cancer »

Dal Settembre 2003 al Luglio 2008

Liceo Scientifico ad indirizzo classico Brocca "Giuseppe Tarantino",
Gravina in Puglia (BA)

Diploma di scuola media superiore. Vote: 100/100

**CAPACITÀ PERSONALI
E COMPETENZE**

LINGUA MADRE

ITALIANO

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
 - Capacità verbali

INGLESE

Eccellente

Eccellente

Eccellente

FIRST Certificate in English
Council of Europe Level B2

Pubblicazioni

- Botticelli A., Borro M., Onesti C.E., Strigari L., Gentile G., Cerbelli B., Romiti A., Occhipinti M., Sebastiani C., Lionetto L., Marchetti L., Simmaco M., Marchetti P., Mazzuca F. Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker? PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105.
- Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. *Anticancer Drugs*. 2016 Nov 11.
- Onesti CE, Iacono D, Angelini S, Lauro S, Mazzotta M, Occhipinti MA, Giusti R, Marchetti P. Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. *Transl Lung Cancer Res* 2016 Dec; 5(6):712-719
- Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F. A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. *Anticancer Drugs*. 2017 Mar 14.
- Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, Di Pietro FR, Rossi A, Simmaco M, Mazzuca F, Marchetti P. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. *Anticancer Res*. 2017 May; 37(5):2633-2639.
- Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? *Oncotarget*. 2017 Nov 1; 8(59):99336-99346.
- Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, Lauro S. Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. *J Thorac Dis*. 2017 Nov; 9(11):E985-E989.
- Occhipinti M, Falcone R, Onesti CE, Marchetti P. Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. *Drug Saf - Case Rep*. 2018
- Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, Nicolazzo C, Coppa A, Giannini G. Coexistence of three EGFR mutations in an NSCLC patient: A brief report. *Int J Biol Markers*. 2018 Jun 1:1724600818782200.
- Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fagnoli MC, Ascierto PA, Ficarella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. *J Immunother Cancer*. 2019 Feb 27;7(1):57.
- Alessandro Parisi, Alessio Cortellini, Michela Roberto, Olga Venditti, Daniele Santini, Emanuela Dell'Aquila, Marco Stellato, Paolo Marchetti, Mario Alberto Occhipinti, Federica Zoratto, Federica Mazzuca, Nicola Tinari, Michele De Tursi, Laura Iezzi, Clara Natoli, Margherita Ratti, Claudio Pizzo, Michele Ghidini, Giampiero Porzio, Corrado Ficarella, Katia Cannita. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. *J Cancer Res Clin Oncol*. 2019 Jul 6.
- Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficarella C, Porzio G, Ascierto PA. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. *J Transl Med*. 2019 Nov 15;17(1):376.

- M Mazzotta, M Filetti, A Rossi, M Roberto, M Occhipinti, A Pernazza, A Di Napoli, S Scarpino, A Vecchione, R Giusti, P Marchetti. Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification. *Annals of Oncology* (Jan 2020).
- A Cortellini, S Buti, M Bersanelli, R Giusti, F Perrone, P Di Marino, N Tinari, M De Tursi, A Grassadonia, K Cannita, A Tessitore, F Zoratto, E Veltri, F Malorgio, M Russano, C Anesi, T Zeppola, M Filetti, P Marchetti, A Botticelli, GC Antonini Cappellini, F De Galitiis, MG Vitale, F Rastelli, F Pergolesi, R Berardi, S Rinaldi, M Tudini, RR Silva, A Pireddu, F Atzori, D Iacono, MR Migliorino, A Gelibter, MA Occhipinti, F Martella, A Inno, S Gori, S Bracarda, C Zannori, C Mosillo, A Parisi, G Porzio, DMallardo, MC Fagnoli, M Tiseo, D Santini, PA Ascierio & C Ficorella . Evaluating the role of FAMIlly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. *January 2020 Oncoimmunology* 9(1).
- Gelibter A, Occhipinti M, Pisegna S, Cortellini A, Cortesi E, Marchetti P. Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. *Lung Cancer Manag* February 2020.
- Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni A, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadri S, E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR , Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. *Adv Ther.* 2020 Mar;37(3):1145-1155.
- Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadri S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. *Expert Opin Biol Ther.* 2020 Mar;20(3):319-326.
- Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Maria Alessandra Calegari, Lisa Salvatore, Giampaolo Tortora, Daniele Rossini, Marco Maria Germani, Alessandra Boccaccino, Emanuela Dell’Aquila, Claudia Fulgenzi, Daniele Santini, Michele De Tursi, Nicola Tinari, Pietro Di Marino, Pasquale Lombardi, Susana Roselló Keränen, Marisol Huerta Álvaro, Ina Valeria Zurlo, Domenico Cristiano Corsi, Alessandra Emiliani, Nicoletta Zanaletti, Teresa Troiani, Pasquale Vitale, Riccardo Giampieri, Filippo Merloni, Mario Alberto Occhipinti, Paolo Marchetti, Michela Roberto, Federica Mazzuca, Michele Ghidini, Alice Indini, Ingrid Garajova, Federica Zoratto, Simona Delle Monache, Giampiero Porzio, Corrado Ficorella. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study. *Cancers* 12 (5), 1259.
- Alessio Cortellini, Alex Friedlaender, Giuseppe L Banna, Giampiero Porzio, Melissa Bersanelli, Federico Cappuzzo, Joachim GJV Aerts, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria R Migliorino, Domenico Galetta, Francesco Passiglia, Rossana Berardi, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Alessandro Inno, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Michele Ghidini, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Mario Alberto Occhipinti, Fabrizio Citarella, Russano Marco, Mariangela Torniai, Luca Cantini, Alessandro Follador, Vincenzo Sforza, Olga Nigro, Miriam G Ferrara, Ettore D’Argento, Alessandro Leonetti, Linda Pettoruti, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Federica Bertolini, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A Belderbos, Marco De Filippis, Cristina Cecchi, Serena Ricciardi, Clelia Dionisi, Alessandro De Toma, Claudia Proto, Alfredo Addeo, Ornella Cantale, Biagio Ricciuti, Carlo Genova, Alessandro Morabito, Daniele Santini, Corrado Ficorella, Katia Cannita. Immune-related adverse events of pembrolizumab in a large real-world cohort of NSCLC patients with a PD-L1 expression $\geq 50\%$ and their relationship with clinical outcomes. *Clinical Lung Cancer* June 2020.
- Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. The 5-Ws of immunotherapy in head and neck cancer. *Critical Reviews in Oncology/Hematology*, 103041.

- D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, M Pallocca, G Corleone, E Krasniqi, L Pizzuti, M Barba, S Carpano, P Vici, M Filetti, R Giusti, A Vecchione, M Occhipinti, A Gelibter, A Botticelli, F De Nicola, L Ciuffreda, F Goeman, E Gallo, P Visca, E Pescarmona, M Fanciulli, R De Maria, P Marchetti, G Ciliberto, M Maugeri-Saccà. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. *Annals of Oncology*, August 2020.
- M Mazzotta, M Filetti, M Occhipinti, D Marinelli, S Scalera, I Terrenato, F Sperati, M Pallocca, F Rizzo, A Gelibter, A Botticelli, G Scafetta, A Di Napoli, E Krasniqi, L Pizzuti, M Barba, S Carpano, P Vici, M Fanciulli, F De Nicola, L Ciuffreda, F Goeman, R De Maria, A Vecchione, R Giusti, G Ciliberto, P Marchetti, M Maugeri-Saccà. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. *Journal for ImmunoTherapy of Cancer* 8(2), August 2020.
- Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Grossi F, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Gwaitoli G, Della Gravara L, Tabbò F, Ricciardi S, De Toma A, Friedlaender A, Petrelli F, Addeo A, Porzio G, Ficarella C. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. *J Immunother Cancer*. 2020 Oct;8(2): e001403.
- Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bissoni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficarella C, Ascierto PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. *J Immunother Cancer* 2020 Nov;8(2):e001361.
- Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficarella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *Eur J Cancer* 2020 Nov 16;142:18-28.
- Marta Brambilla, Giuseppe Lo Russo, Roberto Ferrara, Sara Manglaviti, Marina Chiara Garassino, Mario Occhipinti. Is hyperprogressive disease a specific phenomenon of immunotherapy? *Explor Target Antitumor Ther*. 2020;1:427-433.
- Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, Giusti R, D'Argento E, Grossi F, Santoni M, Catino A, Berardi R, Sforza V, Rossi G, Antonuzzo L, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Follador A, Rastelli F, Chiari R, Gravara LD, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Pensieri MV, Russano M, Cantini L, Nigro O, Leonetti A, Bordi P, Minuti G, Landi L, De Toma A, Donisi C, Ricciardi S, Migliorino MR, Napoli VM, Leone G, Metro G, Banna GL, Friedlaender A, Addeo A, Ficarella C, Porzio G. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. *Thorac Cancer*. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1. PMID: 33527756.
- Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice Labianca, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Gabriella Francesca Greco, Valter Torri, Filippo de Braud, Marina C. Garassino. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *European Journal of Cancer*, 2021.
- Occhipinti, M.; Brambilla, M.; Galli, G.; Manglaviti, S.; Giammaruco, M.; Prelaj, A.; Ferrara, R.; De Toma, A.; Proto, C.; Beninato, T.; Zattarin, E.; Lo Russo, G.; Gelibter, A.J.; Simmaco, M.; Preissner, R.;

Garassino, M.C.; De Braud, F.; Marchetti, P. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *J. Pers. Med.* 2021, 11, 424.

- Sara Manglaviti, Marta Brambilla, Diego Signorelli, Roberto Ferrara, Giuseppe Lo Russo, Claudia Proto, Giulia Galli, Alessandro De Toma, Mario Occhipinti, Giuseppe Viscardi, Teresa Beninato, Emma Zattarin, Marta Bini, Riccardo Lobefaro, Giacomo Massa, Achille Bottiglieri, Giulia Apollonio, Elisa Sottotetti, Rosa Maria Di Mauro, Benedetta Trevisan, Monica Ganzinelli, Alessandra Fabbri, Filippo G.M. de Braud, Marina Chiara Garassino, Arsela Prelaj. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology, *Clinical Lung Cancer*, 2021, ISSN 1525-7304.
- Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Francesca Rastelli, Alain Gelibter, Rita Chiari, Olga Nigro, Michele De Tursi, Sergio Bracarda, Stefania Gori, Francesco Grossi, Melissa Bersanelli, Lorenzo Calvetti, Vincenzo Di Noia, Mario Scartozzi, Massimo Di Maio, Paolo Bossi, Alfredo Falcone, Fabrizio Citarella, Francesco Pantano, Corrado Ficorella, Marco Filetti, Vincenzo Adamo, Enzo Veltri, Federica Pergolesi, Mario Alberto Occhipinti, Linda Nicolardi, Alessandro Tuzi, Pietro Di Marino, Serena Macrini, Alessandro Inno, Michele Ghidini, Sebastiano Buti, Giuseppe Aprile, Eleonora Lai, Marco Audisio, Salvatore Intagliata, Riccardo Marconcini, Davide Brocco, Giampiero Porzio, Marta Piras, Erika Rijavec, Francesca Simionato, Clara Natoli, Marcello Tiseo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. 2021/8/31, *Cancer Immunology, Immunotherapy* 1-10
- Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. *Rivista: Tumori Journal (internazionale)* pubblicata il 29/11/2021. Spagnoletti A, Platania M, Brambilla M, Occhipinti M, Canziani L, Cabras A, Provenzano L, Leone AG, Ambrosini P, Prelaj A.
- Paraneoplastic neurological syndromes in patients affected by SCLC: a case series. *Rivista: Tumori Journal (internazionale)* pubblicata il 23/01/2022. Zanella C, Leone AG, Zambelli L, Bottiglieri A, Canziani L, Brambilla M, Lo Russo G, Platania M, De Braud F, Occhipinti M.
- Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Rivista: Cancers (internazionale)* pubblicata il 16/01/2022. Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli EG, Ganzinelli M, Sozzi G, de Braud FGM, Garassino MC, Restelli M, Pedrocchi ALG, Trovo' F.
- Occhipinti, M., Ferrara, R., Imbimbo, M., Simeon, V., Ficon, G., Marchal, C., Skoetz, N., Viscardi, G. Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. *Cochrane Database of Systematic Reviews*, 2022.
- Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future Oncol.* 2022 Jul;18(23):2593-2604. doi: 10.2217/fon-2021-1454. Epub 2022 Jun 20.
- Prelaj A, Bottiglieri A, Bhat G, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, De Toma A, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, Lo Russo G, Proto C. Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. *Front Oncol.* 2022 Jun 8;12:902967. doi: 10.3389/fonc.2022.902967. PMID: 35756673; PMCID: PMC9215205.
- Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer.* 2022 Jul 21:S1525-7304(22)00155-3. doi: 10.1016/j.clc.2022.07.010. Epub ahead of print. PMID: 35948460.
- Signorelli, D., Ghidotti, P., Proto, C., Brambilla, M., De Toma, A., Ferrara, R., Galli, G., Ganzinelli, M., Lorusso, G., Prelaj, A., Occhipinti, M., Viscardi, G., Capizzuto, V., Pontis, F., Petrarola, I., Ferretti, A. M., Colombo, M. P., Torri, V., Sozzi, G., Fortunato, O. (2022). Circulating CD81-expressing extracellular

vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Frontiers in Immunology*. <https://doi.org/10.3389/fimmu.2022.987639>.

- Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, Di Mauro RM, Ferrara R, Galli G, Signorelli D, De Toma A, Occhipinti M, Brambilla M, Rulli E, Triulzi T, Torelli T, Agnelli L, Brich S, Martinetti A, Dumitrascu AD, Torri V, Pruneri G, Fabbri A, de Braud F, Anichini A, Proto C, Ganzinelli M, Mortarini R, Garassino MC. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. *ESMO Open*. 2022 Dec;7(6):100645. doi: 10.1016/j.esmoop.2022.100645.
- Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. PEOPLE (NCT03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. *J Immunother Cancer*. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833.
- Prelaj A, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, Proto C, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, Beninato T, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Antonia M, Garassino MC, de Braud FGM, Restelli M, Lo Russo G, Ganzinelli M, Trovò F, Pedrocchi ALG. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. *Front Oncol*. 2023 Jan 23;12:1078822. doi: 10.3389/fonc.2022.1078822.
- Filetti M, Occhipinti M, Cirillo A et al. DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis, 10 March 2023, PREPRINT (Version 1) available at Research Square [<https://doi.org/10.21203/rs.3.rs-2651331/v1>]
- Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *J Thorac Oncol*. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009.
- Marta Brambilla, Teresa Beninato, Anna Piemontese, Laura Mazzeo, Chiara Carlotta Pircher, Sara Manglaviti, Paolo Ambrosini, Diego Signorelli, Daniele Lorenzini, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Giuseppe Lo Russo, Elio Gregory Pizzutilo, Monica Ganzinelli, Iliara Grande, Iolanda Capone, Rosa Maria Di Mauro, Elena Conca, Andra Diana Dumitrascu, Caterina Zanella, Rita Leporati, Simone Rota, Marina Chiara Garassino, Paolo Marchetti, Filippo Maria De Braud, Occhipinti M. Exploring the role of immunotherapy-based treatments for advanced non-small cell lung cancer with novel driver alterations. *Clinical Lung Cancer*, 2023, <https://doi.org/10.1016/j.clc.2023.08.004>.
- Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, Mattia Alberto Di Civita, Andrea Torchia, Raffaele Giusti, Alain Jonathan Gelibter, Michela Roberto, Monica Verrico, Enrico Melis, Riccardo Tajè, Fabiana Letizia Cecere, Lorenza Landi, Paola Nisticò, Nicla Porciello, Mario Occhipinti, Marta Brambilla, Patrick M. Forde, Stephen V. Liu, Andrea Botticelli, Silvia Novello, Gennaro Ciliberto, Enrico Cortesi, Francesco Facciolo, Federico Cappuzzo, Daniele Santini, Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials, *Critical Reviews in Oncology/Hematology*, Volume 192, 2023, 104190, <https://doi.org/10.1016/j.critrevonc.2023.104190>.
- Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Sabina Sangaletti, Alice Labianca, Elisa Sottotetti, Marta Brambilla, Mario Occhipinti, Claudia Proto, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Giuseppe Viscardi, Teresa Beninato, Laura Mazzeo, Achille Bottiglieri, Rita Leporati, Giuseppe Fotia, Monica Ganzinelli, Paola Portararo, Marina Chiara Garassino, Filippo G.M. de Braud, Giuseppe Lo Russo, Valter Torri, Roberto Ferrara. High bone tumor burden to identify

advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors, Lung Cancer, Volume 186, 2023, 107417. <https://doi.org/10.1016/j.lungcan.2023.107417>.

- Arselà Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Giulio Metro, Giulia Galli, Francesco Agustoni, Carminia Maria Della Corte, Andrea Spagnoletti, Claudia Giani, Roberto Ferrara, Claudia Proto, Marta Brambilla, Andra Diana Dumitrascu, Alessandro Inno, Diego Signorelli, Elio Gregory Pizzutilo, Matteo Brighenti, Federica Biello, Chiara Bennati, Luca Toschi, Marco Russano, Alessio Cortellini, Chiara Catania, Federica Bertolini, Rossana Berardi, Luca Cantini, Federica Pecci, Marianna Macerelli, Rita Emili, Claudia Bareggi, Francesco Verderame, Antonio Lugini, Salvatore Pisconti, Federica Buzzacchino, Michele Aieta, Alfredo Tartarone, Gianpaolo Spinelli, Emanuele Vita, Salvatore Grisanti, Francesco Trovò, Pietro Auletta, Daniele Lorenzini, Luca Agnelli, Sabina Sangaletti, Francesca Mazzoni, Giuseppina Calareso, Margherita Ruggirello, Gabriella Francesca Greco, Raffaella Vigorito, Mario Occhipinti, Sara Manglaviti, Teresa Beninato, Rita Leporati, Paolo Ambrosini, Roberta Serino, Cecilia Silvestri, Emanuela Zito, Alessandra Chiara Laura Pedrocchi, Vanja Miskovic, Filippo de Braud, Giancarlo Prunerì, Giuseppe Lo Russo, Carlo Genova, Andrea Vingiani. APOLLO 11 Project, Consortium in advanced lung cancer patients treated with innovative therapies: Integration of real-world data and translational research. Clinical Lung Cancer, 2023, ISSN 1525-7304, <https://doi.org/10.1016/j.clc.2023.12.012>.
- Ndembe G, Intini I, Moro M, Grasselli C, Panfili A, Panini N, Blevè A, Occhipinti M, Borzi C, Garassino MC, Marabese M, Canesi S, Scanziani E, Sozzi G, Brogginì M, Ganzinelli M. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 2;43(1):6. doi: 10.1186/s13046-023-02933-5. PMID: 38163906; PMCID: PMC10759660.

PARTECIPAZIONE IN TRIAL CLINICI

Partecipazione in più di 20 trial clinic in accordo con le linee guida ICH-GCP nel ruolo di sub-investigatore.

Sub-Therapeutic Area	Title	Phase	Role	Year	Trial status
Thoracic Tumors	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	III	Sub-Inv	2023	Accrual
Thoracic Tumors	FASTing-like approach to improve the efficacy of maintenance IMMunotherapy in Extensive-stage small cell lung cancer patients not progressing on chemoimmunotherapy induction: the FASTIMMUNE trial	II	Sub-Inv	2023	Accrual
Thoracic Tumors	Circulating microRNAs to choose the IO strategy in PD-L1 \geq 50% NSCLC patients: the Ark clinical trial	II	Sub-Inv	2023	Accrual
Thoracic Tumors	A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy	II	Sub-Inv	2023	Accrual
Thoracic Tumors	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY	III	Sub-Inv	2023	Accrual
Thoracic Tumors	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent	III	Sub-Inv	2022	Accrual

	Chemoradiotherapy followed by MK- 7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC				
Thoracic Tumors	Interrogating circulating lung tumor cells to guide personalized therapies and identify novel targets to hit metastasis initiating cells	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer PAPILLON	III	Sub-Inv	2022	Accrual
Thoracic Tumors	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	III	Sub-Inv	2022	Accrual
Thoracic Tumors	Apollo 11, a consortium of centers involved in the care of lung cancer patients treated with innovative therapies: integration of real world data and translational research	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	Integrative science and artificial intelligence platform to individualize immunotherapy treatment in patients with lung malignancy: the I3LUNG study	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	A randomized, open-label phase 2/3 study comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone in participants with advanced non-small cell lung cancer who have progressed on prior anti-pd-(l)1 therapy and chemotherapy (COSTAR LUNG)	II/III	Sub-Inv	2022	Accrual
Thoracic Tumors	HPD 1 line – Hyperprogressive disease upon first line immunecheckpoint blockade in advance NSCLC patients	Observ	Sub-Inv	2021	Accrual
Thoracic Tumors	A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	III	Sub-Inv	2021	Accrual
Thoracic Tumors	A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma	II	Sub-Inv	2021	Accrual
Thoracic Tumors	Evaluation of the analytical validity of "comprehensive genomic profiling" on circulating tumor DNA for the implementation of liquid biopsy in precision oncology		Sub-Inv	2021	Accrual
Thoracic Tumors	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	II	Sub-Inv	2020	Accrual
Thoracic Tumors	A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	II	Sub-Inv	2020	Accrual
ThoracicTumors	Gender Difference in side effects of	Observ	Sub-Inv	2020	Accrual

	ImmuNotherapy: a possible clue to optimize cancer Treatment (G-DEFINER)				
Thoracic Tumors	Exploiting metformin plus/minus cyclic Fasting Mimicking Diet (FMD) to improve the efficacy of first line chemo-immunotherapy in advanced LKB1-inactive lung adenocarcinoma	II	Sub-Inv	2020	Accrual
Thoracic Tumors	MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC.	II	Sub-Inv	2020	Accrual
Thoracic Tumors	Improving treatment strategies in thymic epithelial tumors: a tyme collaborative effort	II	Sub-Inv	2020	Accrual
Thoracic Tumors	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)	III	Sub-Inv	2020	Accrual
Thoracic Tumors	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)	III	Sub-Inv	2020	Accrual
Thoracic Tumors	Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors	III	Sub-Inv	2020	Accrual
Thoracic Tumors	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	II	Sub-Inv	2020	Accrual
Thoracic Tumors	Phase II, open-label study of atezolizumab in a Cohort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histological subtypes (CHANCE trial)	II	Sub-Inv	2020	Closed
Thoracic Tumors	A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	III	Sub-Inv	2020	Closed
Thoracic Tumors	A PHASE 2, MULTICENTER, OPEN-LABEL, MULTICOHORT STUDY TO ASSESS SAFETY AND EFFICACY OF CC-90011 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH ADVANCED CANCERS	II	Sub-Inv	2020	Closed
Thoracic Tumors	A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)	Observ	Sub-Inv	2020	Closed
Thoracic Tumors	A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER	III	Sub-Inv	2021	Closed
Thoracic Tumors	A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of	III	Sub-Inv	2020	Closed

	pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)				
Thoracic Tumors	A phase IIIB, single arm, multicenter study of atezolizumab (tecentriq) in combination with carboplatin plus etoposide to investigate safety and efficacy in patients with untreated extensive-stage small cell lung cancer - MAURIS	III	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	III	Sub-Inv	2020	Closed
Thoracic Tumors	PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)	III	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)	II	Sub-Inv	2020	Closed
Thoracic Tumors	A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation	IV	Sub-Inv	2020	Closed
Thoracic Tumors	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)	III	Sub-Inv	2020	Closed
Thoracic Tumors	Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)	II	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)	II	Sub-Inv	2020	Closed
Thoracic Tumors	Stromal control of lung cancer seeding through fibroblast reprogramming (AIRC IG 21431)	Observ	Sub-Inv	2020	Closed
Thoracic Tumors	Phase II study to evaluate the activity and safety of Cabozantinib in pretreated, advanced RET-reArranged non-small cell lung cancer patients: CRETA trial	II	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and	II	Sub-Inv	2021	Closed

	Curative Intent Therapy (MERMAID-2)				
Thoracic Tumors	A Phase 3, Randomized Study of Amivantamab Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer MARIPOSA	III	Sub-Inv	2020	Closed
Thoracic Tumors	HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC) (Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC)	II	Sub-Inv	2020	Closed
Thoracic Tumors	Phase II trial of sunitinib in patients with type b3 thymoma or thymic carcinoma in second and further lines (Style trial).	II	Sub-Inv	2020	Closed
Thoracic Tumors	First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy	Observ	Sub-Inv	2020	Closed
Thoracic Tumors	Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)	IV	Sub-Inv	2017	Closed
Thoracic Tumors	A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)	III/IV	Sub-Inv	2018	Closed
Breast	A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases	II	Sub-Inv	2019	Closed

COMPETENZE TECNICHE

Conoscenza ed uso pratico dei più rilevanti programmi informatici Microsoft (es. pacchetto office).

PATENTE DI GUIDA

Patente di guida B

Il sottoscritto, consapevole che – ai sensi dell’art. 76 del D.P.R. 445/2000 - le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità.

Il sottoscritto in merito al trattamento dei dati personali esprime il proprio consenso al trattamento degli stessi nel rispetto delle finalità e modalità di cui al d.lgs. n. 196/2003.